January 3, 2023 News by Lindsey Shapiro, PhD FDA OKs Phase 3 Trial of Masitinib for Progressive Forms of MS The U.S. Food and Drug Administration (FDA) has cleared AB Science to initiate a Phase 3 clinical trial of its investigational treatment masitinibĀ in people with progressive forms of multiple sclerosis (MS). The decision follows approvals in several European countries that will also host trial sites, including…
March 4, 2022 News by Marta Figueiredo, PhD Masitinib Slows Disability Progression in PPMS, Non-active SPMS Masitinib, AB Scienceās experimental oral therapy, significantly slows disability progression in adults with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS), according to final data from the AB07002 Phase 2b/3 clinical trial. These findings, indicating that the trial met its main goal, support…
February 7, 2022 News by Marta Figueiredo, PhD Sweden, Like France, OKs Start of Masitinib Trial in Progressive MS The Swedish Medical Products Agency has approved AB Scienceās request to launch in the country a confirmatory Phase 3 clinical trial of its lead candidate masitinibĀ in adults withĀ primary progressive multiple sclerosisĀ (PPMS) and nonactiveĀ secondary progressive MSĀ (SPMS). The decision comes on the heels of a similar authorization byĀ the…
January 10, 2022 Columns by Ed Tobias MS News That Caught My Eye Last Week: Lemtrada, Music and White Matter, Diagnosing MS AB Science OKād to Start Masitinib Phase 3 Trial for Progressive MS Many of us with multiple sclerosis (MS) have been waiting for another treatment for progressive forms of MS. I hope this brings us another step closer to one. Masitinib is an oral medication that works by blocking…
January 5, 2022 News by Marta Figueiredo, PhD AB Science OK’d to Start Masitinib Phase 3 Trial for Progressive MS The French Health Authority has approved AB Scienceās request to launch a Phase 3 clinical trial to confirm the safety and effectiveness of its lead candidate masitinib in adults with primary progressive multiple sclerosis (PPMS) and nonactive secondary progressive MS (SPMS). āWe are very excited to initiate…
September 17, 2020 News by Marta Figueiredo, PhD #MSVirtual2020 – Masitinib Delays Disability Progression in PPMS, Non-active SPMS AB Scienceās lead candidate masitinibĀ safely and effectively delays disability progression in people withĀ primary progressive multiple sclerosisĀ (PPMS) and non-activeĀ secondary progressive MSĀ (SPMS), according to top-line data from a clinical trial. The therapy was found to significantly lower the risk of first and confirmed (three-month) disability progression, and to reduce…
February 24, 2020 News by Marisa Wexler, MS Masitinib Slows Disability Progression in PPMS and Non-active SPMS, Phase 2/3 Trial Reports AB Science‘sĀ masitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS) at a lower dose of 4.5 mg/kg a day, top-line results from a Phase 2b/3 clinical trial show. Masitinib, formerly known as AB1010, is an oral…
February 14, 2020 News by Ana Pena PhD Ocrevus Use Rises Among New Starters with RRMS, Loses Ground to Other Therapies in PPMS First-line use of Genentech‘s Ocrevus (ocrelizumab) for patients with multiple sclerosis (MS) has remained stable through 2019 compared to 2018, according to the latest Spherix Global Insights‘ report. However, the latest edition of “RealWorld Dynamix: DMT New Starts in Multiple Sclerosis (US),” based…
November 22, 2019 News by Ana Pena PhD Ocrevus Top Choice of US Neurologists for Active SPMS, But Mayzent and Mavenclad Gaining Interest, Report Says Genentech‘sĀ OcrevusĀ (ocrelizumab) continues to be the most prescribed medication to reduce inflammatory disease in people with active secondary progressive multiple sclerosisĀ (SPMS) amongĀ U.S. neurologists, even though Novartis’Ā MayzentĀ (siponimod) and EMD Serono’sĀ MavencladĀ (cladribine) were approved in March to treat this same MS…
June 27, 2018 News by Patricia Inacio, PhD After Ocrevus Approval, New Therapies May Become Available for MS, Report Suggests Genentech‘s OcrevusĀ (ocrelizumab),Ā approved in March 2017, has fueled a sea change in the treatment of multiple sclerosis (MS) patients in the U.S., leading to an increased interest in disease-modifying therapies (DMTs) for progressive forms of MS. Now, other potential treatment choices for progressive MS forms will likely…
January 8, 2018 News by Jose Marques Lopes, PhD Trial of AB Science’s Progressive MS Therapy to Continue Without Additional Patient Requirement A Phase 3 clinical trial evaluating AB Science’sĀ masitinib as a treatment for progressive multiple sclerosis can continue without having to add patients, an independent review board has decided. The decision indicates that the therapy has been effective enough that its population base does not need to be expanded, the…
March 14, 2016 News by Margarida Azevedo, MSc Kinase Inhibitor, Masitinib, Spotted for Potential to Treat Neurological Disorders Like PPMS AB ScienceĀ recently reported the publication of four peer-reviewed and independent research papers that add to the growing recognition of masitinib, the companyās lead compound, as a promising treatment for neurological and neurodegenerative diseases, including progressive multiple sclerosis (MS), Alzheimerās disease (AD), and amyotrophic lateral sclerosis (ALS). Tyrosine kinase inhibitors (TKIs)…
July 24, 2015 News by Maureen Newman Masitinib Shows Promise in Study For Treating Progressive MS Patients Progressive multiple sclerosis patients treated with AB Science’s lead compound AB07002 (masitinib) in a Phase 3 clinical trial showed positive results in a non futility test (a test to determine if an experimental therapy shows some sign of efficacy). With the successful completion of the futility analysis, AB Science is…
October 31, 2014 News by Patricia Inacio, PhD Neuroprotective Qualities of Masitinib Drug in Stroke Encouraging For MS Indication An encouraging experimental drug that is being developed for Multiple Sclerosis continues to show promise in being able to offer neuroprotective benefits — an effect that could slow and eventually cure MS.Ā Masitinib,Ā which is being developed by AB Science forĀ numerous neurological indications, including Alzheimer’s disease, progressive multiple sclerosis, and amyotrophic…